Zydus Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Zydus Lifesciences is navigating a strategic transition towards a higher-margin, specialty-driven portfolio, as highlighted by management's focus on innovative products and biosimilars. This pivot is crucial for sustaining revenue growth amid declining legacy generic sales, particularly in the US market, where competition is intensifying. Despite near-term margin pressures from elevated R&D expenditures and integration costs, management maintains a steady EBITDA margin guidance of 24%. Vista's financial outlook reflects a cautious stance, anticipating moderating revenue growth and continued margin compression, aligning with the company's current trajectory. The Indian pharmaceutical sector's expansion, bolstered by currency depreciation and a strong pipeline of innovative products, provides a supportive backdrop, although rising input costs pose challenges. Over the next 12-24 months, key opportunities include the successful commercialization of Saroglitazar and the integration of Assertio Holdings, while watchpoints involve execution risks related to high-value US launches and competitive pressures in the specialty market
Why We Like This Stock
- Management's focus on high-margin specialty products and biosimilars is expected to enhance revenue potential
- The acquisition of Assertio Holdings strengthens Zydus's position in the US oncology market, providing growth opportunities
- The Indian pharmaceutical sector's expansion and improving pricing power support Zydus's long-term growth strategy
Things To Watch Out For
- Near-term margin pressures are anticipated due to elevated R&D spending and integration costs
- Increased competition in the US generics market is leading to sales declines, impacting revenue growth
- Execution risks related to the timely launch of high-value products could hinder the company's growth trajectory
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 19,547 | 23,242 | 27,148 | 28,219 | 31,750 |
| Profit Before Tax (Cr.) | 4,810 | 6,212 | 7,138 | 3,821 | 5,756 |
| PBT Margin | 24.6% | 26.7% | 2629.3% | 13.5% | 18.1% |
| Net Profit (Cr.) | 3,459 | 4,158 | 5,731 | 3,025 | 4,556 |
| Earnings Per Share | 34.7 | 41.7 | 57.4 | 30.3 | 45.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Bernstein | ▲ Buy | 1,457 | 22-May-2026 |
| CLSA | ▲ Outperform | 1,310 | 12-Aug-2026 |
| Choice Equity | ► Hold | 1,120 | 20-May-2026 |
| Citigroup | ▼ Sell | 1,040 | 12-Aug-2026 |
| Elara Capital | ▲ Buy | 1,311 | 25-May-2026 |
| HDFC Securities | ► Add | 1,140 | 20-May-2026 |
| HSBC | ► Hold | 1,100 | 12-Aug-2026 |
| Investec | ▼ Sell | 1,090 | 12-Aug-2026 |
| Jeffries | ▲ Buy | 1,370 | 12-Aug-2026 |
| Macguire | ▲ Outperform | 1,285 | 12-Aug-2026 |
| Moneycontrol | ▲ Overweight | nan | 12-Aug-2026 |
| Motilal Oswal | ► Neutral | 1,125 | 12-Aug-2026 |
| Nomura | ▲ Buy | 1,180 | 19-May-2026 |
| Nuvama | ▲ Buy | 1,400 | 12-Aug-2026 |
| Prabhudas Liladhar | ► Accumulate | 1,200 | 12-Aug-2026 |
Company Overview
Show Company Profile
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.